蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 2205|回复: 13
收起左侧

[供应商管理] 齐鲁爆炸影响德国药品供应-xplosion of an API Manufacturing Site-

[复制链接]
发表于 2017-2-21 14:02:09 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x

2016年10月,齐鲁公司生产抗菌素Piperacillin的设施爆炸。

Explosion of an API Manufacturing Site: Supply of Medicinal Products Endangered

In the past, if one spoke about supply shortages of medicinal products it was usually with a view to the Third World. But then the issue arrived in the USA. Regularly, diverse medicinal products are not available. We - in Europe - have so far believed that the supply of medicinal products would always be guaranteed: after all, we have a functioning health system. Far from it ... The number of cases and their consequences have reached a new level. Moreover, the focus is moving stronger and stronger to the manufacturing sites.

In October 2016, a facility of the company Qilu manufacturing the antibiotic Piperacillin exploded. Piperacillin  "is a broad-spectrum beta-lactam antibiotic of the ureidopenicillin class. The chemical structure of piperacillin and other ureidopenicillins incorporates a polar side chain that enhances penetration into Gram negative bacteria and reduces susceptibility to cleavage by Gram negative beta lactamase enzymes. [...] piperacillin is sometimes referred to as an "anti-pseudomonal penicillin" (Source: Wikipedia).

This accident at one production site has serious consequences in Germany. The Federal Institute for Drugs and Medical Devices (BfArM) announced that In Germany there is a supply shortage of mono-preparations containing Piperacillin and fixed-dose combination products (piperacillin with the beta lactamase inhibitor). It further states that on the basis of the notice made by the Federal Ministry of Health (BMG) according to § 79 section 5 of the German Medicines Act (AMG), the competent Federal authorities are now entitled to allow a temporary deviation from the AMG (German Drug Law) to allow treatments with medicinal products which are not authorised in Germany.

In one word, in Germany there is such a huge dependency on one single facility in China that a vital medicinal product is no longer available. This means that because of an accident (as in the present case) or GMP non-compliance (in other cases), a whole supply chain even in one of the richest countries in the world can be endangered. Especially the price competition has led to APIs being manufactured in Asia, i.e. in low-wage countries where safety and environmental regulations are far less stringent than in Europe. This is another factor which increases the cost advantage. According to the branch service Apotheke Adhoc, this is not a new situation: one year ago, the Ampicillin/Sulbactam combination was concerned. For around a year, doctors have had to forego fosfomycin because of the disaster in Fukushima. Furthermore, the BMG (German Ministry of Health) has declared a state of emergency already three times so far. The last time was in June. GlaxoSmithKline (GSK) was not able to deliver Infanrix hexa and Sanofi Pasteur MSD Hexyon.

The German legislator is currently examining ways of reducing such risks (and similar activities can be observed in other European countries and in the US). In addition to a reporting obligation regarding supply shortages (which is legally not required in Germany and many other EU countries yet) there should be an obligation to check whether the dependency on a few facilities (e.g. located in India and China) doesn't hinder the guarantee of patient safety. It is hoped that such initiatives won't be taken first when harms to patients have already occurred. Just recall the problems and risks around the manufacture of Heparin in China. They had been known for a long time to insiders. But it was only after Heparin had been falsified in China and led to around 250 deaths in the USA that extensive measures had been taken. At that time, manufacturing Heparin in Europe was unthinkable - mainly because of the costs. Today, Heparin is manufactured in one of the world's countries with the highest labour costs: in Germany - under strict GMP regulations!
回复

使用道具 举报

药生
发表于 2017-2-21 14:03:11 | 显示全部楼层
回复

使用道具 举报

药士
发表于 2017-2-21 14:04:20 | 显示全部楼层
安全生产不能放松
回复

使用道具 举报

发表于 2017-2-21 14:13:28 | 显示全部楼层
国际影响,就像目前国内雾霾在国际影响一样

点评

霾是纯负面的,这次爆炸是停产对供应的影响,不是爆炸本身的负面新闻影响。这则新闻中也折射出民族工业的影响力。虽然,安全方面需要警钟长鸣。  详情 回复 发表于 2017-2-21 15:22
这能一样吗?  详情 回复 发表于 2017-2-21 15:17
回复

使用道具 举报

药徒
发表于 2017-2-21 15:11:52 | 显示全部楼层
出处在哪里?哌拉西林出啥状况
回复

使用道具 举报

药徒
发表于 2017-2-21 15:13:13 | 显示全部楼层
影响力还是杠杠的。
回复

使用道具 举报

药徒
发表于 2017-2-21 15:17:24 | 显示全部楼层
hxnbh 发表于 2017-2-21 14:13
国际影响,就像目前国内雾霾在国际影响一样

这能一样吗?
回复

使用道具 举报

药徒
发表于 2017-2-21 15:22:28 | 显示全部楼层
hxnbh 发表于 2017-2-21 14:13
国际影响,就像目前国内雾霾在国际影响一样

霾是纯负面的,这次爆炸是停产对供应的影响,不是爆炸本身的负面新闻影响。这则新闻中也折射出民族工业的影响力。虽然,安全方面需要警钟长鸣。
回复

使用道具 举报

药徒
发表于 2017-2-21 16:02:55 | 显示全部楼层
回复

使用道具 举报

药徒
发表于 2017-2-21 16:23:37 | 显示全部楼层
回复

使用道具 举报

药士
发表于 2017-2-21 18:05:28 | 显示全部楼层
回复

使用道具 举报

发表于 2017-2-25 08:28:01 | 显示全部楼层

结果一样。雾霾会导致企业停产,企业也面临断货失去客户。
回复

使用道具 举报

发表于 2017-2-25 08:42:49 | 显示全部楼层
能翻译吗,看不懂
回复

使用道具 举报

药神
发表于 2023-5-2 22:11:25 | 显示全部楼层
学习,谢谢楼主分享!
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2024-11-28 20:08

Powered by Discuz! X3.4运维单位:苏州豚鼠科技有限公司

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表